Entera Bio

Entera Bio SGA/Revenue

The SGA to Revenue Ratio of Entera Bio (ENTX) as of Nov 22, 2026 is 13,154.76 %. In the previous year, SGA to Revenue Ratio was 2,814.92 % — a change of 367.32% (higher).

SGA/Revenue

13,154.76 %

YoY

367.32%

Last updated:

SGA to Revenue Ratio of Entera Bio is 2025 13,154.76 % . SGA to Revenue Ratio of Entera Bio was 2024 2,814.92 % . It decreases by 367.32% higher compared to the previous year.

The Entera Bio SGA/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SGA/Revenue
Date
SGA/Revenue
Jan 1, 2018
568.60 USD
Jan 1, 2019
1,813.98 USD
Jan 1, 2020
1,340.00 USD
Jan 1, 2021
996.50 USD
Jan 1, 2022
5,412.69 USD
Jan 1, 2023
31,642.86 USD
Jan 1, 2024
2,814.92 USD
Jan 1, 2025
13,154.76 USD
The Entera Bio SGA/Revenue history
YEARSGA/RevenueYoY
13,154.76 %+367.32%
2,814.92 %-91.10%
31,642.86 %+484.61%
5,412.69 %+443.17%
996.50 %-25.63%
1,340.00 %-26.13%
1,813.98 %+219.03%
568.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

SGA to Revenue Ratio of Entera Bio is 13,154.76 % in 2025.

SGA to Revenue Ratio of Entera Bio changed from 2,814.92 % to 13,154.76 %, representing a 367.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of SGA to Revenue Ratio Entera Bio since 2006 – with annual values, charts, and detailed analysis.

The SGA/Revenue ratio shows what percentage of revenue is consumed by selling, general, and administrative costs. Lower ratios indicate greater operating efficiency.

A 'good' varies by industry and company stage. On Eulerpool, you can compare SGA to Revenue Ratio's Entera Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate SGA to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for SGA to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Entera Bio

All Key Metrics — Entera Bio